FDA Denies Approval of MDMA-Assisted Therapy for PTSD.
The American journal of nursing November 1, 2024 DOI: 10.1097/01.naj.0001081684.80872.ce via PubMed
Summary
AI-generated from the abstractThe U.S. Food and Drug Administration declined to approve the use of MDMA-assisted therapy for PTSD, citing safety concerns and methodological problems in the clinical trials. The decision highlights ongoing debates about how to evaluate and regulate psychedelic treatments for mental health conditions.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | PTSD Treatment Clinical trials Drug regulation Mental health |
| Key finding | The FDA refused approval for MDMA-assisted therapy for PTSD, pointing to potential dangers and research flaws. |
Abstract
The agency cited potential dangers and flaws in research methodology.